Cargando…

Primary follicular lymphoma of the prostate presenting with elevated PSA and a PI-RADS 3 lesion on MRI: A case report

Prostate cancer is the most common malignancy diagnosed in men. PI-RADS 3 lesions on multiparametric MRI, when histologically proven malignant, overwhelmingly represent prostatic adenocarcinoma. Primary lymphoma of the prostate, especially follicular lymphoma, is exceedingly rare. To our knowledge,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jia, Hanna, Roberson, Daniel, Luo, Xunda, Kovell, R. Caleb, Hartner, Lee, Harryhill, Joseph F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464876/ https://www.ncbi.nlm.nih.gov/pubmed/36105544 http://dx.doi.org/10.1016/j.eucr.2022.102195

Ejemplares similares

Comparison of PSA density and lesion volume strategies for selecting men with equivocal PI-RADS 3 lesions on bpMRI for biopsies
por: Kortenbach, Karen-Cecilie, et al.
Publicado: (2022)

Detection of clinically significant prostate cancer with PI-RADS v2 scores, PSA density, and ADC values in regions with and without mpMRI visible lesions
por: Westphalen, Antonio C., et al.
Publicado: (2019)

Evaluation of a multiparametric MRI radiomic-based approach for stratification of equivocal PI-RADS 3 and upgraded PI-RADS 4 prostatic lesions
por: Brancato, Valentina, et al.
Publicado: (2021)

MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions?
por: Schoots, Ivo G.
Publicado: (2018)

Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease
por: Schoots, Ivo G., et al.
Publicado: (2018)

MRI/PET Imaging in elevated PSA and localized prostate cancer: a narrative review
por: Regmi, Subodh K., et al.
Publicado: (2021)

Considering Predictive Factors in the Diagnosis of Clinically Significant Prostate Cancer in Patients with PI-RADS 3 Lesions
por: Natale, Caleb, et al.
Publicado: (2021)

The Relationship between Prostate Biopsy Results and PSA and Free PSA Ratio Changes in Elevated Serum PSA Patients with and without Antibiotherapy
por: Duran, Mesut Berkan, et al.
Publicado: (2020)

Prostate biopsy for elevated prostate specific antigen (PSA) – Indian perspective
por: Ragavan, N.
Publicado: (2014)

Development and external validation of a novel nomogram to predict prostate cancer in biopsy‐naïve patients with PSA <10 ng/ml and PI‐RADS v2.1 = 3 lesions
por: Hu, Can, et al.
Publicado: (2022)

Improving the detection rate of prostate cancer in the gray zone of PI-RADS v2 and serum tPSA by using prostate-specific antigen–age volume
por: Lu, Yuan-Fei, et al.
Publicado: (2019)

Early Experience with MRI-ultrasound Fusion-guided Prostate Biopsy in Japanese Men with Elevated PSA Levels
por: Tamada, Tsutomu, et al.
Publicado: (2019)

Equivocal PI-RADS Three Lesions on Prostate Magnetic Resonance Imaging: Risk Stratification Strategies to Avoid MRI-Targeted Biopsies
por: Osses, Daniël F., et al.
Publicado: (2020)

Serum miRNAs Support the Indication for MRI-Ultrasound Fusion-Guided Biopsy of the Prostate in Patients with Low-PI-RADS Lesions
por: Keck, Bastian, et al.
Publicado: (2021)

Correlation between Intraprostatic PSMA Uptake and MRI PI-RADS of [(68)Ga]Ga-PSMA-11 PET/MRI in Patients with Prostate Cancer: Comparison of PI-RADS Version 2.0 and PI-RADS Version 2.1
por: Zhao, Jing, et al.
Publicado: (2020)

Comparison of different thresholds of PSA density for risk stratification of PI-RADSv2.1 categories on prostate MRI
por: Girometti, Rossano, et al.
Publicado: (2022)

Prostate MRI based on PI-RADS version 2: how we review and report
por: Steiger, Philipp, et al.
Publicado: (2016)

Clinical Utility of Prostate Health Index for Diagnosis of Prostate Cancer in Patients with PI-RADS 3 Lesions
por: Lee, Chung-Un, et al.
Publicado: (2022)

Can a prostate biopsy be safely deferred on PI-RADS 1,2 or 3 lesions seen on pre-biopsy mp-MRI?
por: Abdul Raheem, Rickaz, et al.
Publicado: (2022)

Improving the understanding of PI-RADS in practice: characters of PI-RADS 4 and 5 lesions with negative biopsy
por: Wang, Yu-Hao, et al.
Publicado: (2023)

The role of PSA density in the MRI pathway for prostate cancer diagnostics
por: Cash, Hannes, et al.
Publicado: (2022)

Combining clinical and MRI data to manage PI-RADS 3 lesions and reduce excessive biopsy
por: Yang, Shuo, et al.
Publicado: (2020)

Significance of Serum Testosterone for Prostate-Specific Antigen (PSA) Elevation and Prediction of Prostate Cancer in Patients with PSA Above 10 ng/ml
por: Koo, Jin Mo, et al.
Publicado: (2010)

Validation of the PI-RADS language: predictive values of PI-RADS lexicon descriptors for detection of prostate cancer
por: Rudolph, Madhuri M., et al.
Publicado: (2020)

Value of an online PI-RADS v2.1 score calculator for assessment of prostate MRI
por: Barth, Borna K., et al.
Publicado: (2021)

Machine Learning and Clinical-Radiological Characteristics for the Classification of Prostate Cancer in PI-RADS 3 Lesions
por: Gravina, Michela, et al.
Publicado: (2022)

Study of iron metabolism based on T2* mapping sequences in PI-RADS 3 prostate lesions
por: D, Wenhao, et al.
Publicado: (2023)

Effective control of recurrent and metastatic GU SCC by employing a multimodal approach in a patient with a history of radiation and transscrotal surgery for stage I seminoma
por: Roberson, Daniel, et al.
Publicado: (2022)

The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL
por: Wang, Zhi-bing, et al.
Publicado: (2021)

Correction to: The role of PSA density in the MRI pathway for prostate cancer diagnostics
por: Cash, Hannes, et al.
Publicado: (2023)

Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI?
por: Viana, Publio Cesar Cavalcanti, et al.
Publicado: (2019)

Evaluation of the PI-RADS Scoring System for Classifying mpMRI Findings in Men with Suspicion of Prostate Cancer
por: Junker, Daniel, et al.
Publicado: (2013)

Efficacy of PI-RADS in prebiopsy prostate-MRI at a urological cancer centre: a comparison with histology
por: Patel, MD, et al.
Publicado: (2015)

Multiparametric MRI for Prostate Cancer Characterization: Combined Use of Radiomics Model with PI-RADS and Clinical Parameters
por: Woźnicki, Piotr, et al.
Publicado: (2020)

Utility of Clinical–Radiomic Model to Identify Clinically Significant Prostate Cancer in Biparametric MRI PI-RADS V2.1 Category 3 Lesions
por: Jin, Pengfei, et al.
Publicado: (2022)

The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level—Can it rule out clinically significant prostate cancer?
por: Abd-Alazeez, Mohamed, et al.
Publicado: (2014)

Prostate Cancer Development Is Not Affected by Statin Use in Patients with Elevated PSA Levels
por: Meijer, Dennie, et al.
Publicado: (2019)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

Pre-biopsy MRI as an adjunct for cancer detection in men with elevated PSA and no previous biopsy
por: Uriburu-Pizarro, Facundo, et al.
Publicado: (2017)

Prostate-specific antigen kinetics contributes to decision making for biopsy referral: the predictive implication for PSA retest in patients with elevated PSA levels
por: Kobayashi, Minoru, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tfsdvn4jvrl07r34m4prjiu1sv